Abstract
We report our experience with the use of recombinant activated factor VII (rFVIIa) during cardiac surgery in a 4.5-year-old boy with severe congenital FXI deficiency and a congenital heart disease. After weaning the patient from cardiopulmonary bypass, the first intravenous dose of rFVIIa (90 μg/kg) was administered. This same dosage was repeated eight more times, at 2- to 4-hour intervals postoperatively. There was no bleeding during and after surgery. rFVIIa treatment may be used successfully in children with severe FXI deficiency in major operations such as open heart surgery.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bern MM, Sahud M, Zhukov O, Qu K, Mitchell W Jr (2005) Treatment of factor XI inhibitor using recombinant activated factor VIIa. Haemophilia 11:20–25
Billon S, Le Niger C, Escoffre-Barbe M, Vicariot M, Abgrall JF (2001) The use of recombinant factor VIIa (NovoSeven) in a patient with a factor XI deficiency and a circulating anticoagulant. Blood Coagul Fibrinolysis 12:551–553
Brown SA (2005) What dose of recombinant activated factor VII should be used in patients with factor XI deficiency? Haemophilia 11:430–431
Ferster A, Capouet V, Deville A, Fondu P, Corazza F (1993) Cardiac surgery with extracorporeal circulation in severe factor VII deficiency. Haemostasis 23:65–68
Hedner U (1990) Factor VIIa in the treatment of haemophilia. Blood Caogul Fibrinolysis 1:307–317
Lawler P, White B, Pye S, Hermans C, Riddell A, Costello C, Brown S, Lee CA (2002) Successful use of recombinant factor VIIa in a patient with inhibitor secondary to severe factor XI deficiency. Haemophilia 8:145–148
O’Connell NM (2003) Factor XI deficiency—from molecular genetics to clinical management. Blood Coagul Fibrinolysis 14(suppl 1):S59–S64
Pychynska-Pokorska M, Moll JJ, Krajewski W, Jarosik P (2004) The use of recombinant coagulation factor VIIa in uncontrolled postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass. Pediatr Crit Care Med 5:246–250
Ramadan KM, McNulty O, Anderson JA, Jones FG, Winter PC (2006) A novel factor XI gene mutation associated with mild factor XI deficiency in a symptomatic patient. Blood Coagul Fibrinolysis 17:499–502
Razon Y, Erez E, Vidne B, Birk E, Katz J, Tamari H, Dagan O (2005) Recombinant factor VIIa (NovoSeven) as a hemostatic agent after surgery for congenital heart disease. Paediatr Anaesth 15:235–240
Salomon O, Seligsohn U (2004) New observations on factor XI deficiency. Haemophilia 10(suppl 4):184–187
Schulman S (1998) Safety, efficacy and lessons from continuous infusion with rFVIIa. rFVIIa-CI Group. Haemophilia 4:564–567
Schulman S, Nemeth G (2006) An illustrative case and a review on the dosing of recombinant factor VIIa in congenital factor XI deficiency. Haemophilia 12:223–227
Tokunaga C, Hiramatsu Y, Horigome H, Takahashi-Igari M, Noma M, Sakakibara Y (2003) Palliative open heart surgery in an infant with factor VII deficiency. Ann Thorac Surg 76:2093–2094
Yilmaz BT, Alioglu B, Ozyurek E, Akay HT, Mercan S, Ozbek N (2005) Successful use of recombinant factor VIIa (NovoSeven) during cardiac surgery in a pediatric patient with Glanzmann thrombasthenia. Pediatr Cardiol 26:843–845
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Avci, Z., Malbora, B., Gokdemir, M. et al. Successful Use of Recombinant Factor VIIa (NovoSeven®) During Cardiac Surgery in a Pediatric Patient with Congenital Factor XI Deficiency. Pediatr Cardiol 29, 220–222 (2008). https://doi.org/10.1007/s00246-007-9081-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00246-007-9081-3